Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review.
4 affiliations
- 1Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. [email protected].
- 2Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- 3Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
- 4Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Abstract
Background
Chemotherapy-induced alopecia (CIA) is common, distressing, and markedly impairs patients' quality of life. Although scalp cooling is the only approved preventive strategy, its effectiveness and accessibility remain limited. Therefore, alternative pharmacologic approaches, such as minoxidil and prostaglandin analogs, have been explored.Methods
This scoping review aimed to explore the available evidence on minoxidil's efficacy and safety and the potential role of prostaglandin analogs in alopecia. PubMed, Cochrane Library, Medical Online, and Ichushi-Web were comprehensively searched from inception to February 2026. Studies evaluating minoxidil in CIA and prostaglandin analogs in any alopecia type were included. Case reports, case series, and non-human studies were excluded.Results
Seven studies were included. Five studies evaluated minoxidil in CIA, including two randomized controlled trials and three retrospective studies on prophylactic and therapeutic use, respectively. Prophylactic topical minoxidil did not markedly prevent CIA but was associated with earlier hair regrowth. In contrast, therapeutic use-particularly of oral minoxidil-improved hair density and treatment response. No serious adverse events were reported, although cardiovascular effects remain a concern with oral formulations. Two randomized controlled trials evaluated prostaglandin analogs in non-chemotherapy-related alopecia and showed markedly improved hair density and regrowth. However, no study directly assessed their efficacy in CIA.Conclusions
Minoxidil may be beneficial for hair regrowth in CIA but shows limited preventive efficacy. Prostaglandin analogs are promising but untested in this setting. Future studies should evaluate their role, particularly in combination with minoxidil, to address the current evidence gap and improve outcomes for patients with CIA.
Related
- Occipital hairline changes in women with frontal fibrosing alopecia receiving low-dose oral minoxidil.
- Gastrointestinal Side Effects of Low-Dose Oral Minoxidil in Patients with Alopecia: An Underrecognized Association.
- Periocular morphology during long-term topical ophthalmic treatment: associations with prostaglandin analogs, preservatives, and eyelid manipulation
- 8,9-EET analogs protect glomerular cells from doxorubicin-induced toxicity
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
BibTeX
@article{iimura2026minoxidil,
title = {{Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review.}},
author = {Yohei Iimura and Tomoya Yokota and Hironobu Hashimoto and Seiichiro Kuroda},
journal = {Current oncology reports},
year = {2026},
month = oct,
doi = {10.1007/s11912-026-01841-z},
url = {https://europepmc.org/article/MED/42873375},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review.
AU - Yohei Iimura
AU - Tomoya Yokota
AU - Hironobu Hashimoto
AU - Seiichiro Kuroda
PY - 2026
DA - 2026/10/14
JO - Current oncology reports
DO - 10.1007/s11912-026-01841-z
UR - https://europepmc.org/article/MED/42873375
AB - Background Chemotherapy-induced alopecia (CIA) is common, distressing, and markedly impairs patients' quality of life. Although scalp cooling is the only approved preventive strategy, its effectiveness and accessibility remain limited. Therefore, alternative pharmacologic approaches, such as minoxidil and prostaglandin analogs, have been explored.Methods This scoping review aimed to explore the available evidence on minoxidil's efficacy and safety and the potential role of prostaglandin analogs in alopecia. PubMed, Cochrane Library, Medical Online, and Ichushi-Web were comprehensively searched from inception to February 2026. Studies evaluating minoxidil in CIA and prostaglandin analogs in any alopecia type were included. Case reports, case series, and non-human studies were excluded.Results Seven studies were included. Five studies evaluated minoxidil in CIA, including two randomized controlled trials and three retrospective studies on prophylactic and therapeutic use, respectively. Prophylactic topical minoxidil did not markedly prevent CIA but was associated with earlier hair regrowth. In contrast, therapeutic use-particularly of oral minoxidil-improved hair density and treatment response. No serious adverse events were reported, although cardiovascular effects remain a concern with oral formulations. Two randomized controlled trials evaluated prostaglandin analogs in non-chemotherapy-related alopecia and showed markedly improved hair density and regrowth. However, no study directly assessed their efficacy in CIA.Conclusions Minoxidil may be beneficial for hair regrowth in CIA but shows limited preventive efficacy. Prostaglandin analogs are promising but untested in this setting. Future studies should evaluate their role, particularly in combination with minoxidil, to address the current evidence gap and improve outcomes for patients with CIA.
SN - 1523-3790
SN - 1534-6269
ER -